GlassScriptPhysician profile
Jeffery L Barber
NPI 1942267513
$12,254.59
in general payments reported to CMS, 2019-2025
49 companies · $2,281 in 2025
The $2,281 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $1,280 · 2021: $1,874 · 2022: $1,835 · 2023: $1,903 · 2024: $1,571 · 2025: $2,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,634 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,633.69 |
| Education | $121.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,472.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,264.38 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,138.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $888.17 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $784.30 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $589.85 | 2025 | Intellis Adaptivestim, Inceptiv |
| Pfizer INC. | $485.09 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.30 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $381.05 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.03 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $337.17 | 2019-2022 | |
| Abbott Laboratories | $317.57 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $298.90 | 2020-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $274.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $206.58 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.